India Gets First Dengue Vaccine as DCGI Approves QDENGA

India Gets Its First Dengue Vaccine

India achieved a major milestone in public health after the Drug Controller General of India (DCGI) approved QDENGA, the country’s first dengue vaccine. Japanese pharmaceutical company Takeda developed the vaccine. The approval covers people aged 4 to 60 years. Moreover, health experts believe the approval will strengthen India’s fight against dengue.

Dengue cases continue to rise across several states every year. Therefore, experts believe vaccination, along with mosquito control measures, can reduce severe dengue infections and hospitalisations.

What Is QDENGA?

QDENGA is a tetravalent dengue vaccine. It protects people against all four dengue virus serotypes. Unlike some earlier dengue vaccines, QDENGA does not require pre-vaccination testing. People do not need to confirm a previous dengue infection before receiving the vaccine. Therefore, eligible individuals can receive the vaccine without prior screening.

Furthermore, more than 40 countries have already approved QDENGA. Several countries also include it in public and private immunisation programmes. Consequently, India’s approval marks another important step in global dengue prevention.

Who Can Receive the Vaccine?

The DCGI approved QDENGA for people between 4 and 60 years of age. Doctors administer the vaccine in two doses. They recommend a three-month gap between each dose.

Meanwhile, health authorities are expected to announce details about vaccine availability, pricing, and rollout in India. State governments and healthcare providers may also release implementation plans in the coming months.

Why the Approval Is Important

Dengue remains a major public health concern in India, especially during the monsoon season. Infected Aedes mosquitoes spread the disease. It can cause high fever, severe headache, muscle pain, joint pain, skin rashes, and serious complications.

Therefore, experts believe India’s first dengue vaccine can reduce severe illness and hospital admissions. However, they also advise people to continue preventive measures. People should remove stagnant water, use mosquito repellents, and follow official health guidelines.

What Happens Next?

Following the India First Dengue Vaccine approval, attention will now shift to the commercial launch and distribution of QDENGA across the country. Takeda has previously partnered with Biological E to expand manufacturing capacity for the vaccine, which may support future supply in India.

Consequently, healthcare experts believe that the introduction of QDENGA could play an important role in India’s long-term dengue prevention strategy. While vaccination alone cannot eliminate dengue, it represents a significant advancement in protecting vulnerable populations and reducing the overall impact of the disease.